Chromosomal effects of non-alkylating drug exposure in oncology personnel

Melissa A. McDiarmid, Bonnie Rogers, Marc S. Oliver

Research output: Contribution to journalArticle

Abstract

Therapy-related leukemia has been a recognized sequela of cancer treatment for decades with "signature" abnormalities of chromosomes 5, 7, and 11 observed in treated patients. Risk to oncology personnel handling anti-cancer agents has also been documented by non-specific measures of genotoxicity in blood and urine. Using chromosomal markers applied in clinical practice, we previously demonstrated in oncology workers, a dose-related increase in abnormalities of chromosomes 5 and 7, known to be targets of alkylating agent exposure. In the analysis presented here, we extended that work to also assess damage resulting from non-alkylating drug exposure. Peripheral blood lymphocytes from oncology personnel (N=63) and non-exposed controls (N=46) was collected and examined using the fluorescent in situ hybridization technique with probes for targets on chromosomes 5, 7, and 11. Participants recorded drug handling events over a 6 week period. Important co-variates were considered. Examining chromosomal outcomes as a function of drug handling frequency, we employed Poisson Regression to obtain incident rate ratios (IRRs) for selected drug handling frequencies. We found a dose-related increase in the IRR for aberrations in all three chromosomes 5, 7, and 11, reaching statistical significance for chromosome 5, as a function of non-alkylating drug handling. This suggests that the targeting of chromosome 5 is not limited to alkylating agent exposure, as some recent evidence in treated patients has also shown. Thus, the pattern of insult observed in treated patients appears to extend to oncology personnel exposed in the workplace. Environ. Mol. Mutagen. 55:369-374, 2014.

Original languageEnglish (US)
Pages (from-to)369-374
Number of pages6
JournalEnvironmental and Molecular Mutagenesis
Volume55
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Chromosomes, Human, Pair 5
Chromosomes, Human, Pair 7
Chromosomes, Human, Pair 11
Pharmaceutical Preparations
Alkylating Agents
Mutagens
Fluorescence In Situ Hybridization
Workplace
Neoplasms
Leukemia
Urine
Lymphocytes
Therapeutics

Keywords

  • Anti-cancer drugs
  • Chromosome
  • Oncology worker

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Epidemiology
  • Genetics(clinical)

Cite this

Chromosomal effects of non-alkylating drug exposure in oncology personnel. / McDiarmid, Melissa A.; Rogers, Bonnie; Oliver, Marc S.

In: Environmental and Molecular Mutagenesis, Vol. 55, No. 4, 2014, p. 369-374.

Research output: Contribution to journalArticle

McDiarmid, Melissa A. ; Rogers, Bonnie ; Oliver, Marc S. / Chromosomal effects of non-alkylating drug exposure in oncology personnel. In: Environmental and Molecular Mutagenesis. 2014 ; Vol. 55, No. 4. pp. 369-374.
@article{a04dcd753eba46c88fe516ad6860ae96,
title = "Chromosomal effects of non-alkylating drug exposure in oncology personnel",
abstract = "Therapy-related leukemia has been a recognized sequela of cancer treatment for decades with {"}signature{"} abnormalities of chromosomes 5, 7, and 11 observed in treated patients. Risk to oncology personnel handling anti-cancer agents has also been documented by non-specific measures of genotoxicity in blood and urine. Using chromosomal markers applied in clinical practice, we previously demonstrated in oncology workers, a dose-related increase in abnormalities of chromosomes 5 and 7, known to be targets of alkylating agent exposure. In the analysis presented here, we extended that work to also assess damage resulting from non-alkylating drug exposure. Peripheral blood lymphocytes from oncology personnel (N=63) and non-exposed controls (N=46) was collected and examined using the fluorescent in situ hybridization technique with probes for targets on chromosomes 5, 7, and 11. Participants recorded drug handling events over a 6 week period. Important co-variates were considered. Examining chromosomal outcomes as a function of drug handling frequency, we employed Poisson Regression to obtain incident rate ratios (IRRs) for selected drug handling frequencies. We found a dose-related increase in the IRR for aberrations in all three chromosomes 5, 7, and 11, reaching statistical significance for chromosome 5, as a function of non-alkylating drug handling. This suggests that the targeting of chromosome 5 is not limited to alkylating agent exposure, as some recent evidence in treated patients has also shown. Thus, the pattern of insult observed in treated patients appears to extend to oncology personnel exposed in the workplace. Environ. Mol. Mutagen. 55:369-374, 2014.",
keywords = "Anti-cancer drugs, Chromosome, Oncology worker",
author = "McDiarmid, {Melissa A.} and Bonnie Rogers and Oliver, {Marc S.}",
year = "2014",
doi = "10.1002/em.21852",
language = "English (US)",
volume = "55",
pages = "369--374",
journal = "Environmental and Molecular Mutagenesis",
issn = "0893-6692",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Chromosomal effects of non-alkylating drug exposure in oncology personnel

AU - McDiarmid, Melissa A.

AU - Rogers, Bonnie

AU - Oliver, Marc S.

PY - 2014

Y1 - 2014

N2 - Therapy-related leukemia has been a recognized sequela of cancer treatment for decades with "signature" abnormalities of chromosomes 5, 7, and 11 observed in treated patients. Risk to oncology personnel handling anti-cancer agents has also been documented by non-specific measures of genotoxicity in blood and urine. Using chromosomal markers applied in clinical practice, we previously demonstrated in oncology workers, a dose-related increase in abnormalities of chromosomes 5 and 7, known to be targets of alkylating agent exposure. In the analysis presented here, we extended that work to also assess damage resulting from non-alkylating drug exposure. Peripheral blood lymphocytes from oncology personnel (N=63) and non-exposed controls (N=46) was collected and examined using the fluorescent in situ hybridization technique with probes for targets on chromosomes 5, 7, and 11. Participants recorded drug handling events over a 6 week period. Important co-variates were considered. Examining chromosomal outcomes as a function of drug handling frequency, we employed Poisson Regression to obtain incident rate ratios (IRRs) for selected drug handling frequencies. We found a dose-related increase in the IRR for aberrations in all three chromosomes 5, 7, and 11, reaching statistical significance for chromosome 5, as a function of non-alkylating drug handling. This suggests that the targeting of chromosome 5 is not limited to alkylating agent exposure, as some recent evidence in treated patients has also shown. Thus, the pattern of insult observed in treated patients appears to extend to oncology personnel exposed in the workplace. Environ. Mol. Mutagen. 55:369-374, 2014.

AB - Therapy-related leukemia has been a recognized sequela of cancer treatment for decades with "signature" abnormalities of chromosomes 5, 7, and 11 observed in treated patients. Risk to oncology personnel handling anti-cancer agents has also been documented by non-specific measures of genotoxicity in blood and urine. Using chromosomal markers applied in clinical practice, we previously demonstrated in oncology workers, a dose-related increase in abnormalities of chromosomes 5 and 7, known to be targets of alkylating agent exposure. In the analysis presented here, we extended that work to also assess damage resulting from non-alkylating drug exposure. Peripheral blood lymphocytes from oncology personnel (N=63) and non-exposed controls (N=46) was collected and examined using the fluorescent in situ hybridization technique with probes for targets on chromosomes 5, 7, and 11. Participants recorded drug handling events over a 6 week period. Important co-variates were considered. Examining chromosomal outcomes as a function of drug handling frequency, we employed Poisson Regression to obtain incident rate ratios (IRRs) for selected drug handling frequencies. We found a dose-related increase in the IRR for aberrations in all three chromosomes 5, 7, and 11, reaching statistical significance for chromosome 5, as a function of non-alkylating drug handling. This suggests that the targeting of chromosome 5 is not limited to alkylating agent exposure, as some recent evidence in treated patients has also shown. Thus, the pattern of insult observed in treated patients appears to extend to oncology personnel exposed in the workplace. Environ. Mol. Mutagen. 55:369-374, 2014.

KW - Anti-cancer drugs

KW - Chromosome

KW - Oncology worker

UR - http://www.scopus.com/inward/record.url?scp=84898058224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898058224&partnerID=8YFLogxK

U2 - 10.1002/em.21852

DO - 10.1002/em.21852

M3 - Article

C2 - 24449410

AN - SCOPUS:84898058224

VL - 55

SP - 369

EP - 374

JO - Environmental and Molecular Mutagenesis

JF - Environmental and Molecular Mutagenesis

SN - 0893-6692

IS - 4

ER -